Developer docs
API playgroundTry for free, no card

Search company profiles

Genenta Science

Full company profile

uuid0000z5n

Namestring
Genenta Science
Legal namestring
Genenta Science S.p.A.
Websiteurl
genenta.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Genenta Science S.p.A. (Nasdaq: GNTA), headquartered in Milan and founded in 2014, is undergoing a strategic transformation from a clinical-stage immuno-oncology biotech into a Nasdaq-listed industrial consolidator rebranding as Saentra Forge. Its original biotechnology platform, Temferon, is a first-in-class autologous cell and gene therapy using gene-modified hematopoietic stem and progenitor cells (HSPCs) to express interferon-alpha locally within the solid tumor microenvironment via Tie2-expressing monocytes, with dual transcriptional and post-transcriptional regulation; the platform also underpins a clinically validated LVV Plasmid DNA technology originally developed by co-founder Professor Luigi Naldini. Following a January 2026 strategic pivot, the company is consolidating Italian companies operating in sectors protected under Italy's Golden Power framework, completing acquisitions of ATC (a NATO-qualified tactical firearms manufacturer) in January 2026 and a 51% controlling stake in Sòphia High Tech (an EN9100 and ESA-certified aerospace and defense additive-manufacturing specialist) in April 2026, while engaging DC Advisory to externalize the original biotech assets through partnerships or licensing. The group generates revenue primarily through Sòphia's hardware sales into European aerospace prime contractors and ESA programs, supplemented by ATC's institutional defense procurement and government channel sales, with a stated target to roughly double Sòphia's revenue base and headcount by 2027.

Short descriptiontext

Genenta Science (Nasdaq: GNTA), rebranding as Saentra Forge, is a Milan-based industrial consolidator acquiring Italian companies in defense, aerospace, and national security sectors protected under Italy's Golden Power framework, with operating subsidiaries in tactical firearms (ATC) and aerospace additive manufacturing (Sòphia High Tech), while externalizing its original Temferon gene-therapy biotech platform.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMilan, Italy
HQ citystring
Milan
HQ countrystring
Italy
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell gene therapy, immuno-oncology platform, aerospace defense manufacturing, industrial consolidator, precision tactical systems
Industry3 codes
PRIMARYIMABAHAB
Tactical & Strategic Missile Systems
SECONDARYIMABAOAE
Precision Strike & Fire Control Systems
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biotechnology and Defense Manufacturing
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biotechnology Clinical Development
TypeSubscription Recurring
Description

Pre-revenue clinical-stage biotech company developing Temferon for solid tumors. Revenue generation through potential partnerships, licensing, or eventual product commercialization. Currently exploring external partnerships to monetize biotech assets.

european-biotechnology.com
2Defense and Aerospace Manufacturing
TypeHardware Sales
Description

Through acquired entities (ATC, Sòphia High Tech), the company generates revenue from manufacturing and selling precision tactical systems, aerospace components, and defense products to institutional, defense, and professional markets.

genenta.com
3Industrial Consolidation Services
TypeLicensing Royalties
Description

Acquiring majority stakes in profitable private companies at private market valuations, integrating them within a Nasdaq-listed industrial group to build value through operational expertise and long-term development.

markets.ft.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Temferon™
Description

First-in-class cell therapy platform for targeted interferon-alpha delivery using gene-modified hematopoietic stem cells for treatment of solid tumors including glioblastoma and renal cell carcinoma.

genenta.com
+2 more records
Core offering1 text field

Genenta Science develops Temferon, a first-in-class autologous cell and gene therapy platform using gene-modified hematopoietic stem cells to deliver interferon-alpha directly to solid tumors. Through acquired subsidiaries ATC (precision tactical firearms) and Sòphia High Tech (aerospace and defense components), the company operates as a strategic industrial consolidator targeting Italy's Golden Power-protected sectors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 29% two-year survival rate vs ~14% in historical uMGMT standard-of-care cohorts
+4 more records
Product overview1 text field

Genenta Science, evolving into Saentra Forge, operates as a strategic industrial consolidator focused on defense, aerospace, and national security sectors. The company's portfolio includes three main products: (1) Temferon™ - a first-in-class autologous cell and gene therapy platform for solid tumor treatment using gene-modified hematopoietic stem cells; (2) ATC - a high-precision manufacturer of tactical rifles and special-forces weapon systems; and (3) Sòphia High Tech - an aerospace and defense engineering company specializing in precision mechanical components and additive manufacturing for space programs. The company is transitioning from its original biotechnology focus toward becoming an industrial aggregator for strategic technologies protected under Italy's Golden Power framework.

Product and service3 records
1Temferon
CategoryCell and Gene Therapy
Description

First-in-class, one-time autologous cell and gene therapy using gene-modified hematopoietic stem cells (HSPCs) to deliver interferon-alpha (IFN-α) directly to solid tumors. The therapy reprograms the tumor microenvironment by exploiting Tie2-expressing monocytes as precision delivery vehicles, enabling localized and sustained therapeutic activity while minimizing systemic toxicity. Currently in clinical trials for glioblastoma multiforme and metastatic renal cell carcinoma.

2ATC (Armi Tattiche Custom) Tactical Firearms
CategoryDefense Manufacturing
Description

Italian high-precision manufacturer of tactical rifles, chassis systems, optics mounts, bipods, and related accessories for special forces and competition-grade sporting firearms. Operates with vertical integration from CAD/CAM design through precision CNC machining to finishing, assembly, and final inspection. Holds NATO qualifications and Italian Ministry of Defense authorization.

3Sòphia High Tech Aerospace and Defense Components
CategoryAerospace and Defense Manufacturing
Description

Italian aerospace and defense engineering and manufacturing company producing critical mechanical components for space and defense systems. Capabilities include advanced manufacturing techniques including metal 3D printing (Selective Laser Melting), CNC precision machining, and exotic materials processing (titanium, Inconel, tungsten, specialized copper alloys). Certified to EN9100 aerospace standard and ECSS-Q-ST-70-80C for ESA additive manufacturing.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-27
Description

Genenta (evolving into Saentra Forge) signed binding offer to acquire controlling stake in Sòphia High Tech, an Italian aerospace and defense engineering and manufacturing company. €6 million initial investment for 19.9% stake with path to 51% majority ownership. Sòphia builds critical mechanical components for space and defense systems including precision parts for rockets, satellites, and aircraft. The transaction aims to scale production and maintain Italy's national security technological assets.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-27
Description

Initial investment of up to €5.1 million in ATC, a NATO-qualified manufacturer of tactical rifles and special-forces weapon systems. Genenta entered a binding agreement to fund ATC with goal of acquiring controlling position upon achievement of performance milestones. ATC is a high-precision manufacturer with UAMA and SeRMI export-control licenses and Italian Ministry of Defense authorization.

3DC Advisory
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-01-27
Description

Genenta hired DC Advisory to monetize its biotech assets through partnerships while positioning as a strategic consolidator. DC Advisory is engaged to explore strategic options for the original biotechnology platform derived from Professor Luigi Naldini's research.

globenewswire.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-24
Description

Expanded strategic collaboration focused on off-the-shelf lentiviral vector Plasmid DNA technology for advanced therapy development. Building on existing successful partnership in plasmid DNA manufacturing, Anemocyte gains access to Genenta's clinically validated LVV Plasmid DNA technology platform developed from research by co-founder Professor Luigi Naldini. The collaboration aims to offer reliable and scalable materials from R&D to GMP grade to Anemocyte's clients across the life sciences industry.

Strategic tierCoreTypeOthers
Description

Sòphia High Tech is one of the few companies in Europe qualified to 3D-print flight-ready space hardware to ESA and NASA standards, certified to ECSS-Q-ST-70-80C specification for additive manufacturing.

Strategic tierCoreTypeOthers
Description

Sòphia serves AVIO for rocket propulsion components and the Multi-Purpose Green Engine (MPGE) program focused on regenerative combustion chambers realized entirely through additive manufacturing.

Strategic tierCoreTypeOthers
Description

Sòphia collaborates with Thales Alenia Space on the ZIRÈ satellite scientific payload for low-energy gamma particle detection, developed in collaboration with Gran Sasso Science Institute, INFN.

8Gran Sasso Science Institute / INFN
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration on ZIRÈ satellite scientific payload for low-energy gamma particle detection with Domenico Borrelli (Sòphia CTO) leading technical execution.

genenta.com
Strategic tierCoreTypeOthers
Description

Sòphia developing Crystal Eye Cherenkov telescope, a scientific instrument for gamma particle detection, for Avio S.p.a.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1bluebird bio
TypeDirect peer
Description

Clinical-stage gene and cell therapy company developing autologous gene-modified cell therapies for severe genetic diseases and oncology. Highly comparable to Genenta on autologous gene-modified cell therapy platform technology and clinical-stage biotech risk profile.

TypeBroad incumbent
Description

Clinical-stage gene editing company developing CRISPR/Cas9-based therapies across hemoglobinopathies, oncology, and regenerative medicine. Comparable as a Nasdaq-listed gene therapy platform with multi-indication pipeline strategy.

TypeBroad incumbent
Description

Clinical-stage gene editing company developing in vivo and ex vivo CRISPR-based therapies. Comparable on gene therapy platform, oncology applications, and Nasdaq-listed clinical-stage biotech profile.

TypeEmerging player
Description

Clinical-stage gene editing company developing CRISPR-based and engineered cell therapies for serious diseases. Comparable on gene-modified cell therapy approach and Nasdaq-listed clinical-stage biotech profile.

TypeEmerging player
Description

Clinical-stage precision genetic medicine company developing base editing therapies. Comparable as a Nasdaq-listed biotech using advanced gene engineering platforms with oncology and rare disease applications.

TypeEmerging player
Description

Clinical-stage gene editing company developing in vivo therapies for cardiovascular disease. Comparable on gene therapy platform architecture and Nasdaq-listed clinical-stage profile, though focused on different therapeutic area.

TypeOthers
Description

Strategic partner providing cell and gene therapy manufacturing services including LVV plasmid DNA. Highly relevant ecosystem participant given Genenta's expanded plasmid DNA collaboration.

8Cobra Biologics (Charles River Laboratories)
TypeBroad incumbent
Description

CDMO providing viral vector and plasmid DNA manufacturing services for gene and cell therapy developers. Comparable as a viral vector/plasmid DNA manufacturing platform serving the same advanced therapy ecosystem as Genenta's LVV Plasmid DNA platform.

TypeEmerging player
Description

Clinical-stage cell therapy company using Cell Squeeze technology to engineer immune cells. Comparable on cell engineering approach; board member Armon Sharei founded SQZ, providing direct ecosystem linkage.

10Fiocchi Munizioni
TypeDirect peer
Description

Italian manufacturer of ammunition and tactical products serving defense, law enforcement, and sporting markets. Comparable as a defensive/sporting firearms industrial peer — Paolo Salvato (ATC board member) was previously CEO of Fiocchi, creating direct ecosystem overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genenta Science

Biotechnology and Defense Manufacturinggenenta.com

Genenta Science (Nasdaq: GNTA), rebranding as Saentra Forge, is a Milan-based industrial consolidator acquiring Italian companies in defense, aerospace, and national security sectors protected under Italy's Golden Power framework, with operating subsidiaries in tactical firearms (ATC) and aerospace additive manufacturing (Sòphia High Tech), while externalizing its original Temferon gene-therapy biotech platform.

What Genenta Science does

Genenta Science S.p.A. (Nasdaq: GNTA), headquartered in Milan and founded in 2014, is undergoing a strategic transformation from a clinical-stage immuno-oncology biotech into a Nasdaq-listed industrial consolidator rebranding as Saentra Forge. Its original biotechnology platform, Temferon, is a first-in-class autologous cell and gene therapy using gene-modified hematopoietic stem and progenitor cells (HSPCs) to express interferon-alpha locally within the solid tumor microenvironment via Tie2-expressing monocytes, with dual transcriptional and post-transcriptional regulation; the platform also underpins a clinically validated LVV Plasmid DNA technology originally developed by co-founder Professor Luigi Naldini. Following a January 2026 strategic pivot, the company is consolidating Italian companies operating in sectors protected under Italy's Golden Power framework, completing acquisitions of ATC (a NATO-qualified tactical firearms manufacturer) in January 2026 and a 51% controlling stake in Sòphia High Tech (an EN9100 and ESA-certified aerospace and defense additive-manufacturing specialist) in April 2026, while engaging DC Advisory to externalize the original biotech assets through partnerships or licensing. The group generates revenue primarily through Sòphia's hardware sales into European aerospace prime contractors and ESA programs, supplemented by ATC's institutional defense procurement and government channel sales, with a stated target to roughly double Sòphia's revenue base and headcount by 2027.

Genenta Science firmographics

Firmographics
Name
Genenta Science
Legal name
Genenta Science S.p.A.
Website
https://genenta.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Genenta Science (Nasdaq: GNTA), rebranding as Saentra Forge, is a Milan-based industrial consolidator acquiring Italian companies in defense, aerospace, and national security sectors protected under Italy's Golden Power framework, with operating subsidiaries in tactical firearms (ATC) and aerospace additive manufacturing (Sòphia High Tech), while externalizing its original Temferon gene-therapy biotech platform.
Ownership category
akta.pro rank

Genenta Science industry classification

Industry
Product category
Biotechnology and Defense Manufacturing
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYIMABAHAB
Tactical & Strategic Missile Systems
SECONDARYIMABAOAE
Precision Strike & Fire Control Systems
SECONDARYHLAAACAN
Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Cell gene therapy
  • Immuno-oncology platform
  • Aerospace defense manufacturing
  • Industrial consolidator
  • Precision tactical systems

Where Genenta Science is headquartered

Location

Headquarters

HQ city
Milan
HQ country
Italy
HQ region
Europe

Offices5 records

Markets served

Genenta Science business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure

Revenue model

  1. Biotechnology Clinical Development: Pre-revenue clinical-stage biotech company developing Temferon for solid tumors. Revenue generation through potential partnerships, licensing, or eventual product commercialization. Currently exploring external partnerships to monetize biotech assets.
  2. Defense and Aerospace Manufacturing: Through acquired entities (ATC, Sòphia High Tech), the company generates revenue from manufacturing and selling precision tactical systems, aerospace components, and defense products to institutional, defense, and professional markets.
  3. Industrial Consolidation Services: Acquiring majority stakes in profitable private companies at private market valuations, integrating them within a Nasdaq-listed industrial group to build value through operational expertise and long-term development.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels6 records

Genenta Science product offering

Product offering

Core offering

Genenta Science develops Temferon, a first-in-class autologous cell and gene therapy platform using gene-modified hematopoietic stem cells to deliver interferon-alpha directly to solid tumors. Through acquired subsidiaries ATC (precision tactical firearms) and Sòphia High Tech (aerospace and defense components), the company operates as a strategic industrial consolidator targeting Italy's Golden Power-protected sectors.

Product overview

Genenta Science, evolving into Saentra Forge, operates as a strategic industrial consolidator focused on defense, aerospace, and national security sectors. The company's portfolio includes three main products: (1) Temferon™ - a first-in-class autologous cell and gene therapy platform for solid tumor treatment using gene-modified hematopoietic stem cells; (2) ATC - a high-precision manufacturer of tactical rifles and special-forces weapon systems; and (3) Sòphia High Tech - an aerospace and defense engineering company specializing in precision mechanical components and additive manufacturing for space programs. The company is transitioning from its original biotechnology focus toward becoming an industrial aggregator for strategic technologies protected under Italy's Golden Power framework.

Differentiator

Problem solved

Functional benefit

Brands

  • Temferon™: First-in-class cell therapy platform for targeted interferon-alpha delivery using gene-modified hematopoietic stem cells for treatment of solid tumors including glioblastoma and renal cell carcinoma.
  • ATC
  • Sòphia High Tech

Products and services

  • Temferon First-in-class, one-time autologous cell and gene therapy using gene-modified hematopoietic stem cells (HSPCs) to deliver interferon-alpha (IFN-α) directly to solid tumors. The therapy reprograms the tumor microenvironment by exploiting Tie2-expressing monocytes as precision delivery vehicles, enabling localized and sustained therapeutic activity while minimizing systemic toxicity. Currently in clinical trials for glioblastoma multiforme and metastatic renal cell carcinoma.
  • ATC (Armi Tattiche Custom) Tactical Firearms Italian high-precision manufacturer of tactical rifles, chassis systems, optics mounts, bipods, and related accessories for special forces and competition-grade sporting firearms. Operates with vertical integration from CAD/CAM design through precision CNC machining to finishing, assembly, and final inspection. Holds NATO qualifications and Italian Ministry of Defense authorization.
  • Sòphia High Tech Aerospace and Defense Components Italian aerospace and defense engineering and manufacturing company producing critical mechanical components for space and defense systems. Capabilities include advanced manufacturing techniques including metal 3D printing (Selective Laser Melting), CNC precision machining, and exotic materials processing (titanium, Inconel, tungsten, specialized copper alloys). Certified to EN9100 aerospace standard and ECSS-Q-ST-70-80C for ESA additive manufacturing.

Quantifiable outcome

  • 29% two-year survival rate vs ~14% in historical uMGMT standard-of-care cohorts
  • +4 more outcomes

Companies that use Genenta Science

Customer profile

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Genenta Science technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Genenta Science partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Sòphia High Tech S.r.l.coreStrategic or Co-development Partner · 27 March 2026Genenta (evolving into Saentra Forge) signed binding offer to acquire controlling stake in Sòphia High Tech, an Italian aerospace and defense engineering and manufacturing company. €6 million initial investment for 19.9% stake with path to 51% majority ownership. Sòphia builds critical mechanical components for space and defense systems including precision parts for rockets, satellites, and aircraft. The transaction aims to scale production and maintain Italy's national security technological assets.
  • ATC (Armi Tattiche Custom)coreStrategic or Co-development Partner · 27 January 2026Initial investment of up to €5.1 million in ATC, a NATO-qualified manufacturer of tactical rifles and special-forces weapon systems. Genenta entered a binding agreement to fund ATC with goal of acquiring controlling position upon achievement of performance milestones. ATC is a high-precision manufacturer with UAMA and SeRMI export-control licenses and Italian Ministry of Defense authorization.
  • DC AdvisorycoreImplementation/ SI/ Consulting Partner · 27 January 2026Genenta hired DC Advisory to monetize its biotech assets through partnerships while positioning as a strategic consolidator. DC Advisory is engaged to explore strategic options for the original biotechnology platform derived from Professor Luigi Naldini's research.
  • AnemocytecoreStrategic or Co-development Partner · 24 October 2025Expanded strategic collaboration focused on off-the-shelf lentiviral vector Plasmid DNA technology for advanced therapy development. Building on existing successful partnership in plasmid DNA manufacturing, Anemocyte gains access to Genenta's clinically validated LVV Plasmid DNA technology platform developed from research by co-founder Professor Luigi Naldini. The collaboration aims to offer reliable and scalable materials from R&D to GMP grade to Anemocyte's clients across the life sciences industry.
  • European Space Agency (ESA)coreOthersSòphia High Tech is one of the few companies in Europe qualified to 3D-print flight-ready space hardware to ESA and NASA standards, certified to ECSS-Q-ST-70-80C specification for additive manufacturing.
  • AVIO S.p.A.coreOthersSòphia serves AVIO for rocket propulsion components and the Multi-Purpose Green Engine (MPGE) program focused on regenerative combustion chambers realized entirely through additive manufacturing.
  • Thales Alenia SpacecoreOthersSòphia collaborates with Thales Alenia Space on the ZIRÈ satellite scientific payload for low-energy gamma particle detection, developed in collaboration with Gran Sasso Science Institute, INFN.
  • Gran Sasso Science Institute / INFNminorStrategic or Co-development PartnerAcademic collaboration on ZIRÈ satellite scientific payload for low-energy gamma particle detection with Domenico Borrelli (Sòphia CTO) leading technical execution.
  • Avio S.p.A.coreOthersSòphia developing Crystal Eye Cherenkov telescope, a scientific instrument for gamma particle detection, for Avio S.p.a.

Scale indicators14 records

Recent moves9 records

Expansion highlights6 records

Genenta Science competitors and assessment

Company assessment

Direct peers

  • bluebird bio: Clinical-stage gene and cell therapy company developing autologous gene-modified cell therapies for severe genetic diseases and oncology. Highly comparable to Genenta on autologous gene-modified cell therapy platform technology and clinical-stage biotech risk profile.
  • Fiocchi Munizioni: Italian manufacturer of ammunition and tactical products serving defense, law enforcement, and sporting markets. Comparable as a defensive/sporting firearms industrial peer — Paolo Salvato (ATC board member) was previously CEO of Fiocchi, creating direct ecosystem overlap.

Broad incumbents

  • CRISPR Therapeutics: Clinical-stage gene editing company developing CRISPR/Cas9-based therapies across hemoglobinopathies, oncology, and regenerative medicine. Comparable as a Nasdaq-listed gene therapy platform with multi-indication pipeline strategy.
  • Intellia Therapeutics: Clinical-stage gene editing company developing in vivo and ex vivo CRISPR-based therapies. Comparable on gene therapy platform, oncology applications, and Nasdaq-listed clinical-stage biotech profile.
  • Cobra Biologics (Charles River Laboratories): CDMO providing viral vector and plasmid DNA manufacturing services for gene and cell therapy developers. Comparable as a viral vector/plasmid DNA manufacturing platform serving the same advanced therapy ecosystem as Genenta's LVV Plasmid DNA platform.

Emerging players

  • Editas Medicine: Clinical-stage gene editing company developing CRISPR-based and engineered cell therapies for serious diseases. Comparable on gene-modified cell therapy approach and Nasdaq-listed clinical-stage biotech profile.
  • Beam Therapeutics: Clinical-stage precision genetic medicine company developing base editing therapies. Comparable as a Nasdaq-listed biotech using advanced gene engineering platforms with oncology and rare disease applications.
  • Verve Therapeutics: Clinical-stage gene editing company developing in vivo therapies for cardiovascular disease. Comparable on gene therapy platform architecture and Nasdaq-listed clinical-stage profile, though focused on different therapeutic area.
  • SQZ Biotechnologies: Clinical-stage cell therapy company using Cell Squeeze technology to engineer immune cells. Comparable on cell engineering approach; board member Armon Sharei founded SQZ, providing direct ecosystem linkage.

Others

  • Anemocyte: Strategic partner providing cell and gene therapy manufacturing services including LVV plasmid DNA. Highly relevant ecosystem participant given Genenta's expanded plasmid DNA collaboration.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Genenta Science social profiles

Digital presence

Genenta Science compliance and trust

Trust signal

Compliance5 records

Genenta Science financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genenta Science leadership team

Management profile

Number of profiles

Profiles10 records

Genenta Science subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Genenta Science funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genenta Science M&A and investment

M&A and investment

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genenta Science

What does Genenta Science do?

Genenta Science develops Temferon, a first-in-class autologous cell and gene therapy platform using gene-modified hematopoietic stem cells to deliver interferon-alpha directly to solid tumors. Through acquired subsidiaries ATC (precision tactical firearms) and Sòphia High Tech (aerospace and defense components), the company operates as a strategic industrial consolidator targeting Italy's Golden Power-protected sectors.

Is Genenta Science a public or private company?

Genenta Science is a public company. It is classified as public and is currently operating.

When was Genenta Science founded?

Genenta Science was founded in 2014. It employs 11 to 50 people.

Where is Genenta Science based?

Genenta Science is headquartered in Milan, Italy, in the Europe region.

How does Genenta Science make money?

Three revenue lines are on record. Biotechnology Clinical Development is the primary driver. The others are defense and Aerospace Manufacturing and industrial Consolidation Services.

Who are Genenta Science's main competitors?

Direct peers on record are bluebird bio and Fiocchi Munizioni. Broad incumbents are CRISPR Therapeutics, Intellia Therapeutics and Cobra Biologics (Charles River Laboratories). Emerging players are Editas Medicine, Beam Therapeutics, Verve Therapeutics and SQZ Biotechnologies. Anemocyte is listed as an others.

Does Genenta Science have an API?

No public API is recorded for Genenta Science.

What industry is Genenta Science in?

Genenta Science's product category is Biotechnology and Defense Manufacturing. Its primary akta.pro industry code is IMABAHAB, Tactical & Strategic Missile Systems, with a secondary code of IMABAOAE, Precision Strike & Fire Control Systems. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooGenenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial PlatformGenenta Science S.p.A. will trade under the new ticker SAEN on Nasdaq Capital Market starting November 4, 2026, and will do business as Saentra Forge. The name reflects its transformation into a strategic industrial consolidator focused on security-regulated sectors, including aerospace, defense, and biotechnology.Stock TitanGenenta changes ticker to SAEN Nov. 4, adopts Saentra ForgeGenenta Science S.p.A. will change its Nasdaq ticker to SAEN and adopt the business name Saentra Forge, effective November 4, 2026. The change reflects its transformation into a strategic industrial consolidator focused on security-regulated sectors. No shareholder action is required.GlobeNewswireGenenta Unveils Saentra Forge as Its New Brand, Advancing Its Transformation into a Strategic Industrial PlatformGenenta Science S.p.A. will trade on Nasdaq under ticker SAEN, effective November 4, 2026, and will do business as Saentra Forge. The new identity reflects its transformation into a strategic industrial consolidator focused on security-regulated sectors, including aerospace, defense, and biotechnology. No shareholder action is required for the change.Business & FinancialGenenta Science Announces Receipt Of Nasdaq Minimum Bid Price Deficiency NotificationGenenta Science received a Nasdaq notification that its ADS closing bid price fell below $1.00 for 30 consecutive business days from September 3 to October 15, 2026. The company has 180 calendar days until April 14, 2027, to regain compliance, with a possible extension if it meets other listing standards. The board is authorized to implement a reverse stock split within a 1-for-10 to 1-for-20 range.Ticker ReportGenenta Science (GNTA) Expected to Release Quarterly Earnings on WednesdayGenenta Science is expected to report quarterly results on Wednesday, September 2nd, with analysts forecasting a loss of $0.2741 per share. The biotechnology company, which develops in vivo hematopoietic stem cell gene therapies for solid tumors, opened at $1.00 on Monday. Institutional investors hold 15.13% of the stock.Quiver QuantitativeGenenta Science-Backed Sòphia High Tech Reports 2025 Revenue and Profit Growth, Appoints New Board to Drive Aerospace & Defense Expansion | Quiver QuantitativeSòphia High Tech S.r.l., a Genenta Science-backed Italian aerospace and defense manufacturing company, reported strong FY2025 financial results with sales rising 29.3% to €7.17 million and EBITDA growing 68.1% to €1.61 million. The company also appointed a new Board of Directors combining its engineering founders with Genenta's financial and industrial experts to guide its next phase of growth in the Aerospace & Defense market. Genenta currently owns approximately 19% of Sòphia HT with contractual rights to increase its stake to 51%.AInvestGNTA Breaks $2.00 on Near-Zero Volume: A Trap?Genenta Science (GNTA) stock surged 19.6% to $2.01 on June 22, 2026, but on only 6% of its 20-day average volume, indicating a fragile breakout that analysts describe as potentially unsustainable. The technical analysis highlights a disconnect between price momentum and liquidity, with weak institutional support and no clear catalyst driving the move, raising the probability that the $2.00 level is a psychological ceiling rather than a genuine breakout. Traders are advised to monitor the next 1-2 sessions for volume confirmation, with key support zones identified at $1.53-$1.68 and invalidation above $2.00 on 1.5x average volume.Stock TitanGenenta signs binding offer for Sòphia HT stakeGenenta Science (evolving into Saentra Forge) has signed a binding offer to acquire a controlling stake in Sòphia High Tech, an Italian aerospace and defense manufacturing company, through EUR 6.0 million in two reserved capital increases. The transaction, structured in two phases, aims to materially scale Sòphia's production capacity and strengthen its commercial penetration in the European space and defense supply chain. The deal remains subject to confirmatory due diligence, required approvals, and definitive transaction documentation.GlobeNewswireGenenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi NaldiniGenenta Science S.p.A., a Nasdaq-listed Italian biotech company transforming into Saentra Forge, announced it remains engaged with DC Advisory to explore potential collaboration opportunities for its original biotechnology platform derived from research by Professor Luigi Naldini and Bernhard Gentner. However, DC Advisory has not yet identified any potential strategic partners or active discussions regarding Temferon or the platform. The company is pivoting to become a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies, viewing this evolution as serving shareholder interests.Stock TitanGenenta/Saentra Forge keeps Temferon options openGenenta Science (evolving to Saentra Forge) announced it remains actively engaged with DC Advisory to explore collaboration opportunities for its Temferon biotechnology platform, though no potential strategic partners have been identified and no active discussions are currently underway. The company, led by CEO Pierluigi Paracchi, is pivoting from a pure-play biotech to a strategic industrial consolidator targeting Italian national security sectors including biotech, defense, aerospace, and cybersecurity. Founder-scientists Professor Luigi Naldini and Bernhard Gentner oppose any share sales until Temferon receives meaningful third-party validation, as uncertainty surrounds the drug candidate's future development.